Risperidone in the treatment of elderly patients with psychotic disorders

American Journal of Geriatric Psychiatry

Volumn 7, Issue 2, 1999, Pages 132-138

  Madhusoodanan, Subramoniam ^a   Brecher, Martin ^a,b   Brenner, Ronald ^a   Kasckow, John ^a   Kunik, Mark ^a   Negrón, Arnaldo E ^a   Pomara, Nunzio ^a  

^a ST JOHN S EPISCOPAL HOSPITAL   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PSYCHOPHARMACOTHERAPY; QT INTERVAL; RATING SCALE; SCHIZOIDISM; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME;

EID: 0032941890     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-199905000-00006     Document Type: Article

References (17)

1. Pollack B: Clinical relevance of pharmacogenetic variations for geriatric psychopharmacology. Drug Information Journal 1966; 40:669-674
2. Williams G: Care of the aging patient. Prim Care 1989; 16:431-450
3. Zaleon C, Guthrie S: Antipsychotic drug use in older adults. Am J Hosp Pharm 1994; 51:2917-2943
4. Jeste DV, Caligiuri MP, Paulsen JS, et al: Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52:756-765
5. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American Trial. J Clin Psychiatry 1997; 58:538-546
6. Simpson GM, Lindenmayer JR Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997; 17:194-201
7. Berman I, Merson A, Rachov-Pavlov J, et al: Risperidone in elderly schizophrenic patients. AmJ Geriatr Psychiatry 1996; 4:173-179
8. Lacro JP, Eastham JH, Jeste DV, et al: Newer antipsychotics and antidepressants for elderly people. Current Opinion in Psychiatry 1996; 9:290-293
9. Madhusoodanan S, Brenner R, Aroujo L, et al: Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56:514-518
10. Sajatovic M, Ramirez L, Vernon L, et al: Outcome of risperidone therapy in elderly patients with chronic psychosis. Int J Psychiatry Med 1996; 26:309-317
11. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
12. Kay R, Fiszbein A, Opler L: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
13. Chouinard G, Ross-Chouinard A, Annabel L, et al: The Extrapyramidal Symptom Rating Scale (abstract). Can J Neurol Sci 1980; 7:233
14. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
15. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology, Revised. DHEW Pub. No. (ADM) 76-338. Rockville, MD, NIMH, 1976
16. Huang M, Van Peer A, Woestenborghs R, et al: Pharmacokinetics of risperidone in psychogeriatric patients after single and multiple oral administration of 1 mg of risperidone (RIS-DEN-1). Janssen Research Report, March 1993, N96259. Beerse, Belgium, Janssen Research Foundation, 1993, pp 1-38
17. Heykants J, Huang M, Mannens G, et al: The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55(suppl 5):13-17